Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer''s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
最新股票文章
日圓走勢預測：第三方價格目標
2025年截至目前，美元兌日圓（USD/JPY）匯率年內下跌約9.41%。2025年4月25日，日圓兌美元收於142.8790，創下自2024年9月以來的最強水平之一，較2024年7月的高點161.942下跌約11.77%。
11:17, 19 6月 2025
黃金價格走勢分析2025：第三方目標與市場預測
黃金一直被視為經濟不確定時期的重要避險資產。隨著2025年受中央銀行政策轉向、通脹壓力變化以及地緣政治緊張局勢的影響，黃金在交易圈中仍然備受關注。
21:45, 28 4月 2025
評級和評論
評級和評論
